Wells Fargo lowered the firm’s price target on DexCom (DXCM) to $93 from $98 and keeps an Overweight rating on the shares. The firm notes the company reported Q3 sales/EPS beat driven by strong outside-U.S. growth. FY25 guidance was increased to 15% sales growth, but implies 2-year stacked deceleration in the U.S.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXCM:
- DexCom price target lowered to $99 from $106 at Canaccord
- Dexcom’s Stock Weakness Presents a Buy Opportunity Amid Strong Growth Prospects and Strategic Guidance
- Dexcom Reports Strong Q3 2025 Growth and Raises Guidance
- Dexcom’s Strong Q3 Performance and Future Growth Potential Justify Buy Rating
- Closing Bell Movers: Amazon soars to all-time highs on earnings